Different Strategies Using Autoantibodies and/or CT Scan Detection of Lung Cancer
In this trial, the addition of a blood biomarker test is being combined with early LDCT to
determine if screening with combination may result in detection of more lung cancer at an
earlier stage of disease.The study will also assess if the blood test is able to detect lung
cancers in high risk individuals when the LDCT is negative for cancer. There will be
health-economic costs included in the final analysis of study data.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
CT alone vs. both Early CDT-Lung test and CT scan.
Assess the number of lung cancers detected with CT alone vs. with both Early CDT-Lung test and CT scan. Compare positive CT results with positive/negative Early CDT Lung test results and assess ability of the combination to detect earlier stage lung cancer.
Jim Jett, MD
National Jewish Health
United States: Institutional Review Board
|National Jewish Health||Denver, Colorado 80206|